BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leporati P, Fonte R, de Martinis L, Zambelli A, Magri F, Pavesi L, Rotondi M, Chiovato L. A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression. BMC Cancer 2015;15:397. [PMID: 25962899 DOI: 10.1186/s12885-015-1400-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 de Groot S, Röttgering B, Gelderblom H, Pijl H, Szuhai K, Kroep JR. Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma. Cancers (Basel) 2020;12:E3568. [PMID: 33260481 DOI: 10.3390/cancers12123568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Basu R, Kopchick JJ. The effects of growth hormone on therapy resistance in cancer. Cancer Drug Resist 2019;2:827-46. [PMID: 32382711 DOI: 10.20517/cdr.2019.27] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
3 Saeger W, Petersenn S, Schöfl C, Knappe UJ, Theodoropoulou M, Buslei R, Honegger J. Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification. Endocr Pathol 2016;27:115-22. [DOI: 10.1007/s12022-016-9419-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
4 Yuen KC, Heaney AP, Popovic V. Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician. Endocrine 2016;52:194-205. [PMID: 26732039 DOI: 10.1007/s12020-015-0840-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]